Suzuki, Hiroyuki http://orcid.org/0000-0003-2383-5038
Iwamoto, Hideki http://orcid.org/0000-0001-5688-1335
Tanaka, Toshimitsu
Sakaue, Takahiko
Imamura, Yasuko
Masuda, Atsutaka
Nakamura, Toru
Koga, Hironori
Hoshida, Yujin
Kawaguchi, Takumi
Funding for this research was provided by:
Ishibashi Foundation for the Promotion of Science
Takeda Science Foundation
Shinnihon Foundation of Advanced Medical Treatment Research
Kurume University Branding Project
JSPS KAKENHI
Article History
Received: 20 July 2023
Accepted: 24 September 2023
First Online: 21 October 2023
Declarations
:
: Takumi Kawaguchi received lecture fees from Janssen Pharmaceutical K.K., Taisho Pharmaceutical Co., Ltd., Kowa Company, Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., ASKA Pharmaceutical Co., Ltd., AbbVie GK., and EA Pharma Co., Ltd. and a research grant from Eisai Co., Ltd. Yujin Hoshida owns stock in Alentis Therapeutics and Espervita Therapeutics and advises on Helio Genomics, Espertiva Therapeutics, and Roche Diagnostics.
: Study approval statement: all animal experiments were approved by the ethical committee of the Kurume University School of Medicine (Kurume, Japan) (ethical code:2021-049).